Strides’ subsidiary, Strides Pharma Global, has received approval from the Food and Drug Administration for Sevelamer Carbonate for Oral Suspension, 0.8 gm and 2.4 gm, which is the generic of Genzyme’s Renvela.
Sevelamer Carbonate for Oral Suspension is a medication used to manage elevated levels of phosphate in the blood of patients with chronic kidney disease.
When consumed after a meal, the medication binds to dietary phosphate and prevents its absorption thereby managing overall phosphate levels in the blood, the company said.
Sevelamer Carbonate tablets and oral suspension has a combined market value of $ 212 million, per IQVIA.
The products will be manufactured at the company’s facility in Bengaluru, India.